ERYTECH announces the deposit
of its 2021 Universal Registration Document
and sound Form 20-F 2021,
as well as its 2022 financial calendar
Lyon, France), Cambridge, MA (US) the 28 april 2022 – ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage biopharmaceutical company that develops innovative therapies by encapsulating drugs in red blood cells, announces that it has filed with the Autorité des Marchés Financiers (AMF) in France its Universal Registration Document for the financial year ended December 31, 20201 and his form 20-F for the year ended December 31, 2021 near ” Securities and Exchange Commission » (SEC) in the United Statesas well as its 2022 financial calendar
The universal registration document of ERYTECH Pharma, for the financial year ended December 31, 2021, includes in particular:
- The annual financial report;
- The report of the board of directors on corporate governance.
The documents can be viewed on the company’s website at www.erytech.com in the Investors Section. The Universal Registration Document is also available on the AMF website (www.amf-france.org) and the Form 20-F on the website of the Securities and Exchange Commission » (www.sec.gov). A printed version of these documents can be obtained free of charge and upon simple request sent by post to the Company’s head office at the following address: ERYTECH Pharma – Legal Department – Bioserra Building – 60 Avenue Rockefeller – 69008 LYON – France.
Financial Calendar 2022*
- First quarter 2022 business and financial results update: May 12, 2022 (after market close in the United States), followed by a conference call and webcast on May 13, 2022 at 2:30 p.m. (8:30 am New York time)
- Combined General Meeting: June 24, 2022 – 9 a.m. CEST, in Paris
- Second Quarter 2022 Business Update and Financial Highlights: September 12, 2022 (after market close in the United States), followed by a conference call and webcast on September 13, 2022 at 2:30 p.m. from Paris (8:30 a.m., New York time)
- Third Quarter 2022 Business Update and Financial Results: November 8, 2022 (after market close in the United States), followed by a conference call and webcast on November 9, 2022 at 2:30 p.m. 8:30 a.m. New York time)
Information subject to change. About ERYTECH and eryaspase (GRASPA®)
Founded in Lyon in 2004, ERYTECH is a clinical-stage biopharmaceutical company that develops innovative therapies based on red blood cells to fight against cancers and orphan diseases. Leveraging its proprietary ERYCAPS® platform, an innovative technology for encapsulating drugs in red blood cells, ERYTECH is developing a portfolio of product candidates targeting markets with significant unmet medical needs. ERYTECH mainly focuses on the development of products targeting metabolic disturbances in cancer cells, in order to deprive them of the amino acids necessary for their growth and survival.
The Company’s lead product, eryaspase (GRASPA®), consisting of L-asparaginase encapsulated in red blood cells from donors, addresses the altered asparagine and glutamine metabolism of cancer cells. The proof of concept of eryaspase as a metabolic agent against cancer has been established in different trials on acute lymphoblastic leukemia (ALL) and pancreatic cancer. A phase 2 investigator-sponsored study (IST) evaluating the use of eryaspase in patients with ALL who developed hypersensitivity reactions to pegylated asparaginase recently showed positive results, based on which the Company intends to file for approval in the United States and potentially in other territories. A Phase 2 study in metastatic triple-negative breast cancer and an investigator-sponsored Phase 1 clinical study in the first-line treatment of advanced pancreatic cancer are ongoing.
Eryaspase has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity reactions to pegylated asparaginase and for the treatment of cancer of the advanced pancreas. The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of ALL and pancreatic cancer. Eryaspase is not approved in any country.
ERYTECH produces its drug candidates for the treatment of patients in Europe at its GMP-compliant production site in Lyon, France, and for patients in the United States through its long-term supply agreement with Catalent, operating from the former ERYTECH’s GMP production site in Princeton, New Jersey in the United States.
ERYTECH is listed on the Nasdaq Global Select Market in the United States (symbol: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135; symbol: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indices.
|Chief Financial Officer and Director of Operations|
Mathilde Bohin / Louis-Victor Delouvrier
+33 (0)4 78 74 44 38
|[email protected] |
+33 (0)1 44 71 94 94